Table 3.
Subgroup analysis using individual patient data
| Group | Infliximab | Etanercept | p value | ||||
|---|---|---|---|---|---|---|---|
| Number of reported cases | p value | Number of reported cases | p value | ||||
| Time of reepithelialization (days) | |||||||
| Age (years) | 0.788 | 0.553 | 0.566 | ||||
| < 40 | 12 | 10.67 ± 8.92 | 11 | 11.91 ± 5.38 | |||
| ≥ 40 | 8 | 7.75 ± 8.61 | 30 | 10.17 ± 4.60 | |||
| Sex | 0.106 | 0.224 | 0.751 | ||||
| Male | 9 | 12.67 ± 11.09 | 20 | 9.50 ± 3.58 | |||
| Female | 11 | 12.36 ± 16.52 | 21 | 11.71 ± 5.63 | |||
| SCORTEN | – | 0.901 | – | ||||
| 0–1 | – | – | 2 | 13.00 ± 1.41 | |||
| 2 | 4 | 13.25 ± 9.88 | 7 | 9.29 ± 5.99 | |||
| 3 | – | – | 10 | 9.60 ± 4.60 | |||
| 4 | – | – | 7 | 9.86 ± 4.91 | |||
| ≥ 5 | – | – | 10 | 9.50 ± 4.06 | |||
| Days after symptom onset therapy given (days) | – | 0.984 | – | 0.751 | |||
| < 7 | 13 | 11.85 ± 9.35 | 40 | 10.63 ± 4.88 | |||
| ≥ 7 | 7 | 13.71 ± 21.01 | 1 | – | |||
| Concomitant therapies | 0.716 | 0.092 | 0.426 | ||||
| None or supportive therapy | 5 | 6.80 ± 1.48 | 34 | 9.47 ± 2.24 | |||
| Corticosteroids | 9 | 11.00 ± 12.30 | 7 | 13.29 ± 6.21 | |||
| IVIG | 4 | 9.00 ± 5.74 | 1 | – | |||
| Corticosteroids + IVIG | 1 | – | 2 | 13.50 ± 3.54 | |||
| Hospitalization time (days) | |||||||
| Age (years) | 0.329 | 0.561 | 0.802 | ||||
| < 40 | 7 | 18.13 ± 9.52 | 16 | 20.69 ± 12.47 | |||
| ≥ 40 | 4 | 16.50 ± 9.75 | 5 | 23.00 ± 11.29 | |||
| Sex | 0.177 | 0.320 | 0.837 | ||||
| Male | 8 | 17.88 ± 8.49 | 9 | 21.89 ± 13.76 | |||
| Female | 4 | 17.00 ± 11.83 | 12 | 20.75 ± 11.04 | |||
| SCORTEN | – | 0.668 | – | ||||
| 0–1 | 0 | – | 5 | 22.60 ± 13.30 | |||
| 2 | 2 | 27.00 ± 1.14 | 1 | – | |||
| 3 | 1 | – | 5 | 20.80 ± 12.38 | |||
| 4 | 1 | – | 3 | 26.33 ± 22.23 | |||
| ≥ 5 | 0 | – | 0 | – | |||
| Days after symptom onset therapy given (days) | 1.894 | – | – | ||||
| < 7 | 9 | 19.67 ± 7.75 | 16 | 22.13 ± 12.81 | |||
| ≥ 7 | 3 | 31.33 ± 25.75 | 0 | NA | |||
| Concomitant therapies | 0.677 | 0.039 | 0.128 | ||||
| None or supportive therapy | 2 | 10.50 ± 0.71 | 7 | 17.29 ± 9.01 | |||
| Corticosteroids | 4 | 19.75 ± 9.54 | 10 | 18.60 ± 8.63 | |||
| IVIG | 4 | 19.00 ± 11.96 | 1 | – | |||
| Corticosteroids + IVIG | 1 | – | 4 | 34.75 ± 16.28 | |||
| Mortality rate (%) | |||||||
| Age (years) | 0.066 | 0.117 | 0.846 | ||||
| < 40 | 14 | 0% | 19 | 0% | |||
| ≥ 40 | 14 | 35.7% | 40 | 20% | |||
| Sex | 0.691 | 0.684 | 0.335 | ||||
| Male | 12 | 25% | 26 | 15.4% | |||
| Female | 16 | 16% | 34 | 11.8% | |||
| SCORTEN | |||||||
| 0–1 | – | – | – | 5 | 0% | 0.589 | NA |
| 2 | 4 | 0% | 8 | 0% | |||
| 3 | – | – | 16 | 6.25% | |||
| 4 | – | – | 11 | 9.1% | |||
| ≥ 5 | – | – | 11 | 18.2% | |||
| Days after symptom onset therapy given (days) | 0.786 | 0.014 | 0.631 | ||||
| < 7 | 18 | 16.7% | 47 | 10.6% | |||
| ≥ 7 | 8 | 12.5% | 5 | 60% | |||
| Concomitant therapies | 0.100 | 0.084 | 0.442 | ||||
| None or supportive therapy | 7 | 0% | 39 | 5.1% | |||
| Corticosteroids | 11 | 27.3% | 15 | 20% | |||
| IVIG | 6 | 0% | 1 | 0% | |||
| Corticosteroids + IVIG | 4 | 50% | 8 | 25% | |||
| Number of patient-reported sequelae (%) | |||||||
| Age (years) | 0.663 | 0.010 | 0.657 | ||||
| < 40 | 14 | 27.1% | 19 | 36.8% | |||
| ≥ 40 | 14 | 21.4% | 40 | 7.5% | |||
| Sex | 0.381 | 0.642 | 0.012 | ||||
| Male | 12 | 25% | 26 | 19.2% | |||
| Female | 16 | 50% | 34 | 14.7% | |||
| SCORTEN | – | 0.451 | – | ||||
| 0–1 | – | – | 5 | 40% | |||
| 2 | – | – | 8 | 0% | |||
| 3 | – | – | 16 | 6.3% | |||
| 4 | 4 | 75% | 11 | 18.2% | |||
| ≥ 5 | – | – | 11 | 0% | |||
| Days after symptom onset therapy given (days) | 0.946 | 0.459 | 0.080 | ||||
| < 7 | 18 | 38.9% | 47 | 21.3% | |||
| ≥ 7 | 8 | 37.8% | 5 | 0% | |||
| Concomitant therapies | 0.234 | 0.040 | 0.265 | ||||
| None or supportive therapy | 7 | 57.1% | 39 | 7.7% | |||
| Corticosteroids | 11 | 36.4% | 15 | 13.3% | |||
| IVIG | 6 | 50% | 1 | 0% | |||
| Corticosteroids + IVIG | 4 | 25% | 8 | 62.5% | |||
IVIG intravenous immunoglobulin